BA BA - Oric Pharmaceuticals CoFounder Board
| ORIC Stock | USD 10.00 0.01 0.10% |
Insider
BA BA is CoFounder Board of Oric Pharmaceuticals
| Age | 63 |
| Address | 240 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 388 5600 |
| Web | https://www.oricpharma.com |
Oric Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2523) % which means that it has lost $0.2523 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3973) %, meaning that it created substantial loss on money invested by shareholders. Oric Pharmaceuticals' management efficiency ratios could be used to measure how well Oric Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of February 16, 2026, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.54. At present, Oric Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 10.8 M, whereas Total Assets are forecasted to decline to about 212.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andy Porter | Relay Therapeutics | N/A | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Aaqil Anwar | ATAI Life Sciences | N/A | |
| Thomas Catinazzo | Relay Therapeutics | 50 | |
| Madison Crawford | ATAI Life Sciences | N/A | |
| MD LAc | Nektar Therapeutics | 60 | |
| Justin Klee | Amylyx Pharmaceuticals | 35 | |
| Rutul Shah | Precigen | 45 | |
| Alexander Nolte | Syndax Pharmaceuticals | 51 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Rolando MD | ATAI Life Sciences | 63 | |
| Florian Brand | ATAI Life Sciences | 38 | |
| Richard Heyman | Syndax Pharmaceuticals | 69 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Anne Johnson | ATAI Life Sciences | 56 | |
| Thomas Reed | Precigen | 58 | |
| Kevin Brodbeck | Nektar Therapeutics | N/A | |
| Michael Downes | Syndax Pharmaceuticals | N/A | |
| BS CPA | Inhibrx Biosciences | 42 | |
| Keith CPA | Syndax Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.25 |
Oric Pharmaceuticals Leadership Team
Elected by the shareholders, the Oric Pharmaceuticals' board of directors comprises two types of representatives: Oric Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oric. The board's role is to monitor Oric Pharmaceuticals' management team and ensure that shareholders' interests are well served. Oric Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oric Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| BA BA, CoFounder Board | ||
| Matthew Panuwat, Chief Officer | ||
| Scott Lowe, CoFounder Board | ||
| Kevin Brodbeck, Chief Officer | ||
| MD MBA, CEO President | ||
| Lori Friedman, Chief Officer | ||
| Esq JD, G Counsel | ||
| MS MD, Chief Officer | ||
| Richard Heyman, Independent CoFounder | ||
| Edna Maneval, Executive Development | ||
| BA MD, CoFounder Board | ||
| Daniel Iazzetti, VP People |
Oric Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oric Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 690.05 M | ||||
| Shares Outstanding | 97.39 M | ||||
| Shares Owned By Insiders | 6.71 % | ||||
| Shares Owned By Institutions | 93.29 % | ||||
| Number Of Shares Shorted | 21.65 M | ||||
| Price To Book | 2.39 X | ||||
| EBITDA | (126.74 M) | ||||
| Net Income | (127.85 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Will Biotechnology sector continue expanding? Could Oric diversify its offerings? Factors like these will boost the valuation of Oric Pharmaceuticals. Anticipated expansion of Oric directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oric Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Oric Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oric's balance sheet. Smart investors calculate Oric Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Oric Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Oric Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oric Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.